Lipocine Accounts Payable vs Investments Analysis

LPCN Stock

USD 4.80 0.27 5.33%

Lipocine financial indicator trend analysis is infinitely more than just investigating Lipocine recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lipocine is a good investment. Please check the relationship between Lipocine Accounts Payable and its Investments accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Accounts Payable vs Investments

Accounts Payable vs Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lipocine Accounts Payable account and Investments. At this time, the significance of the direction appears to have weak relationship.

The correlation between Lipocine's Accounts Payable and Investments is 0.3. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Investments in the same time period over historical financial statements of Lipocine, assuming nothing else is changed. The correlation between historical values of Lipocine's Accounts Payable and Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Lipocine are associated (or correlated) with its Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Investments has no effect on the direction of Accounts Payable i.e., Lipocine's Accounts Payable and Investments go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Lipocine obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lipocine are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.

Most indicators from Lipocine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lipocine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.At this time, Lipocine's Selling General Administrative is very stable compared to the past year. As of the 23rd of April 2024, Sales General And Administrative To Revenue is likely to grow to 46.82, while Tax Provision is likely to drop 411.40.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	5.3M	4.1M	15.1M	15.8M
Cost Of Revenue	7.7M	8.6M	28.7K	27.2K

Total Operating Expenses Cost Of Revenue

Lipocine fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Debt	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Retained Earnings Total Equity	Short Term Investments	Capital Surpluse	Treasury Stock	Property Plant And Equipment Net	Non Current Assets Total
Total Assets		0.32	0.44	0.96	-0.28	-0.5	-0.54	0.54	0.51	0.4	0.99	0.43	0.52	0.16	0.69	0.2	1.0	0.46	-0.08	0.91	-0.58	0.66	0.66	-0.54	0.21	0.54
Other Current Liab	0.32		0.58	0.27	-0.02	-0.04	-0.31	0.13	0.0	-0.02	0.31	0.08	0.14	-0.11	0.34	0.19	0.34	0.09	0.17	0.26	-0.34	0.36	0.33	-0.51	0.33	-0.03
Total Current Liabilities	0.44	0.58		0.22	-0.23	0.1	-0.7	0.72	0.04	0.14	0.33	0.42	0.41	0.34	0.69	0.85	0.44	0.45	-0.46	0.2	-0.77	0.34	0.66	-0.71	-0.26	0.22
Total Stockholder Equity	0.96	0.27	0.22		-0.26	-0.56	-0.39	0.38	0.52	0.41	0.99	0.36	0.46	0.01	0.56	-0.07	0.96	0.39	0.08	0.95	-0.41	0.65	0.54	-0.39	0.34	0.54
Other Liab	-0.28	-0.02	-0.23	-0.26		-0.14	0.61	-0.47	0.13	-0.69	-0.23	-0.77	-0.75	-0.05	-0.55	-0.09	-0.25	-0.77	-0.17	-0.36	0.55	-0.38	-0.56	0.32	-0.24	-0.37
Net Debt	-0.5	-0.04	0.1	-0.56	-0.14		-0.18	-0.17	-0.97	0.25	-0.58	0.2	0.19	0.21	0.03	0.21	-0.55	0.2	0.13	-0.51	-0.17	0.25	0.04	-0.12	-0.02	0.2
Retained Earnings	-0.54	-0.31	-0.7	-0.39	0.61	-0.18		-0.76	0.07	-0.66	-0.45	-0.87	-0.86	-0.34	-0.95	-0.59	-0.52	-0.88	-0.08	-0.49	0.99	-0.58	-0.95	0.82	-0.27	-0.36
Accounts Payable	0.54	0.13	0.72	0.38	-0.47	-0.17	-0.76		0.29	0.42	0.46	0.68	0.63	0.22	0.79	0.63	0.54	0.7	-0.38	0.48	-0.76	0.25	0.79	-0.48	-0.18	0.26
Cash	0.51	0.0	0.04	0.52	0.13	-0.97	0.07	0.29		-0.27	0.57	-0.16	-0.16	-0.02	0.05	0.01	0.57	-0.16	-0.28	0.45	0.05	-0.3	0.03	0.03	-0.12	-0.22
Other Assets	0.4	-0.02	0.14	0.41	-0.69	0.25	-0.66	0.42	-0.27		0.36	0.9	0.91	0.09	0.6	-0.01	0.35	0.88	0.39	0.55	-0.58	0.66	0.62	-0.32	0.35	0.63
Cash And Short Term Investments	0.99	0.31	0.33	0.99	-0.23	-0.58	-0.45	0.46	0.57	0.36		0.36	0.46	0.08	0.61	0.07	0.99	0.39	0.0	0.94	-0.47	0.62	0.59	-0.47	0.27	0.48
Common Stock Total Equity	0.43	0.08	0.42	0.36	-0.77	0.2	-0.87	0.68	-0.16	0.9	0.36		0.98	0.13	0.79	0.28	0.4	1.0	0.25	0.5	-0.81	0.55	0.8	-0.53	0.27	0.48
Common Stock Shares Outstanding	0.52	0.14	0.41	0.46	-0.75	0.19	-0.86	0.63	-0.16	0.91	0.46	0.98		0.14	0.81	0.23	0.48	0.98	0.3	0.58	-0.81	0.67	0.82	-0.58	0.34	0.55
Other Current Assets	0.16	-0.11	0.34	0.01	-0.05	0.21	-0.34	0.22	-0.02	0.09	0.08	0.13	0.14		0.32	0.54	0.15	0.14	-0.31	0.01	-0.38	0.11	0.31	-0.31	-0.2	0.11
Other Stockholder Equity	0.69	0.34	0.69	0.56	-0.55	0.03	-0.95	0.79	0.05	0.6	0.61	0.79	0.81	0.32		0.53	0.68	0.81	0.01	0.64	-0.96	0.66	1.0	-0.83	0.3	0.47
Total Liab	0.2	0.19	0.85	-0.07	-0.09	0.21	-0.59	0.63	0.01	-0.01	0.07	0.28	0.23	0.54	0.53		0.2	0.31	-0.61	-0.1	-0.67	0.07	0.5	-0.59	-0.46	0.05
Total Current Assets	1.0	0.34	0.44	0.96	-0.25	-0.55	-0.52	0.54	0.57	0.35	0.99	0.4	0.48	0.15	0.68	0.2		0.43	-0.08	0.9	-0.56	0.61	0.65	-0.54	0.21	0.47
Common Stock	0.46	0.09	0.45	0.39	-0.77	0.2	-0.88	0.7	-0.16	0.88	0.39	1.0	0.98	0.14	0.81	0.31	0.43		0.2	0.51	-0.83	0.58	0.82	-0.55	0.24	0.53
Property Plant Equipment	-0.08	0.17	-0.46	0.08	-0.17	0.13	-0.08	-0.38	-0.28	0.39	0.0	0.25	0.3	-0.31	0.01	-0.61	-0.08	0.2		0.2	0.02	0.25	0.04	-0.06	0.87	-0.1
Net Tangible Assets	0.91	0.26	0.2	0.95	-0.36	-0.51	-0.49	0.48	0.45	0.55	0.94	0.5	0.58	0.01	0.64	-0.1	0.9	0.51	0.2		-0.46	0.66	0.65	-0.41	0.45	0.48
Retained Earnings Total Equity	-0.58	-0.34	-0.77	-0.41	0.55	-0.17	0.99	-0.76	0.05	-0.58	-0.47	-0.81	-0.81	-0.38	-0.96	-0.67	-0.56	-0.83	0.02	-0.46		-0.59	-0.94	0.86	-0.19	-0.4
Short Term Investments	0.66	0.36	0.34	0.65	-0.38	0.25	-0.58	0.25	-0.3	0.66	0.62	0.55	0.67	0.11	0.66	0.07	0.61	0.58	0.25	0.66	-0.59		0.65	-0.56	0.43	0.77
Capital Surpluse	0.66	0.33	0.66	0.54	-0.56	0.04	-0.95	0.79	0.03	0.62	0.59	0.8	0.82	0.31	1.0	0.5	0.65	0.82	0.04	0.65	-0.94	0.65		-0.81	0.33	0.45
Treasury Stock	-0.54	-0.51	-0.71	-0.39	0.32	-0.12	0.82	-0.48	0.03	-0.32	-0.47	-0.53	-0.58	-0.31	-0.83	-0.59	-0.54	-0.55	-0.06	-0.41	0.86	-0.56	-0.81		-0.32	-0.25
Property Plant And Equipment Net	0.21	0.33	-0.26	0.34	-0.24	-0.02	-0.27	-0.18	-0.12	0.35	0.27	0.27	0.34	-0.2	0.3	-0.46	0.21	0.24	0.87	0.45	-0.19	0.43	0.33	-0.32		0.02
Non Current Assets Total	0.54	-0.03	0.22	0.54	-0.37	0.2	-0.36	0.26	-0.22	0.63	0.48	0.48	0.55	0.11	0.47	0.05	0.47	0.53	-0.1	0.48	-0.4	0.77	0.45	-0.25	0.02

Click cells to compare fundamentals

Lipocine Account Relationship Matchups

Lipocine fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	25.4M	52.5M	37.5M	23.0M	29.7M
Other Current Liab	449.3K	1.7M	1M	1.1M	1.2M	1.5M
Total Current Liabilities	5.0M	6.6M	5.6M	1.7M	2.6M	3.4M
Total Stockholder Equity	6.3M	15.3M	45.6M	35.6M	20.4M	24.6M
Net Debt	(2.6M)	(13.6M)	(639.7K)	(3.1M)	(4.8M)	(5.0M)
Retained Earnings	(151.1M)	(172.0M)	(172.7M)	(183.4M)	(199.8M)	(189.8M)
Accounts Payable	1.2M	1.6M	1.3M	600.4K	1.4M	798.8K
Cash	9.7M	19.2M	3.0M	3.1M	4.8M	9.2M
Cash And Short Term Investments	14.1M	19.7M	44.6M	32.5M	22.0M	26.6M
Common Stock Total Equity	2.2K	3.8K	7.0K	8.8K	10.2K	10.7K
Common Stock Shares Outstanding	1.5M	3.3M	5.1M	5.2M	5.3M	5.5M
Liabilities And Stockholders Equity	19.7M	25.4M	52.5M	37.5M	23.0M	29.7M
Other Current Assets	545.9K	661.3K	1.5M	945.3K	773.4K	1.0M
Other Stockholder Equity	157.4M	187.4M	218.2M	219.1M	220.1M	147.6M
Total Liab	13.4M	10.0M	6.9M	1.9M	2.6M	5.1M
Total Current Assets	19.6M	25.3M	46.4M	34.1M	22.9M	28.8M
Accumulated Other Comprehensive Income	(963.0)	(38.0)	(18.0K)	(20.3K)	7.3K	7.6K
Common Stock	3.8K	7.0K	8.8K	8.9K	8.9K	9.3K
Property Plant Equipment	19.0K	3.6K	7.2K	131.6K	118.4K	124.4K
Net Tangible Assets	6.3M	15.3M	45.6M	35.6M	41.0M	27.0M
Retained Earnings Total Equity	(138.1M)	(151.1M)	(172.0M)	(172.7M)	(155.4M)	(163.2M)
Short Term Investments	4.3M	450.0K	41.7M	29.4M	17.3M	15.1M
Capital Surpluse	147.5M	157.4M	187.4M	218.3M	251.0M	143.4M
Property Plant And Equipment Net	3.6K	0.0	7.2K	131.6K	116.1K	63.4K
Non Current Assets Total	27.3K	23.8K	6.1M	3.4M	139.8K	132.9K
Property Plant And Equipment Gross	3.6K	1.1M	1.2M	1.3M	1.3M	1.4M
Net Receivables	16.5K	391.0	247.3K	659.9K	52.3K	49.6K
Net Invested Capital	13.4M	20.9M	47.9M	35.6M	20.4M	27.8M
Net Working Capital	14.7M	18.7M	40.8M	32.5M	20.2M	25.5M
Short Long Term Debt Total	7.1M	5.6M	2.3M	17.2K	15.4K	14.7K
Capital Stock	3.8K	7.0K	8.8K	8.9K	8.9K	7.2K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lipocine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lipocine's short interest history, or implied volatility extrapolated from Lipocine options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:

How To Invest In Lipocine

Details

Is Lipocine Stock a good investment?

Details

What is Lipocine's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Lipocine Stock analysis

When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Global Correlations Find global opportunities by holding instruments from different markets
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities

Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.14)

Revenue Per Share

(0.54)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.37)

Return On Equity

(0.58)

The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lipocine Accounts Payable vs Investments Analysis

Accounts Payable vs Investments

Accounts Payable vs Investments Correlation Analysis

Correlation Coefficient

Accounts Payable

Investments

Lipocine fundamental ratios Correlations

Lipocine Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lipocine fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Lipocine Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Common Stock	+ 1.0	Common Stock Total Equity
Capital Surpluse	+ 1.0	Other Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Retained Earnings Total Equity	+ 0.99	Retained Earnings

Cash	- 0.97	Net Debt
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Capital Surpluse	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Capital Surpluse	- 0.94	Retained Earnings Total Equity
Common Stock	- 0.88	Retained Earnings